Physician profile
Nathan A Gray
NPI 1952347999
$3,314.47
in general payments reported to CMS, 2019-2025
38 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $684 · 2021: $982 · 2022: $523 · 2023: $376 · 2024: $397 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $681.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $585.30 | 2021-2024 | |
| Glaxosmithkline, LLC. | $386.00 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $240.65 | 2020-2023 | |
| Pfizer INC. | $145.36 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $143.61 | 2022-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $119.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.54 | 2020-2023 | Ofev |
| Abbott Laboratories | $95.70 | 2022-2025 | Freestyle Libre 3 |
| Heartflow, INC. | $85.87 | 2025 | |
| Radius Health, INC. | $70.56 | 2020-2022 | |
| Allergan, INC. | $53.42 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $52.71 | 2021 | |
| Esperion Therapeutics, INC. | $43.94 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $43.85 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.